Factors driving the growth of the plasma therapy market include rising incidences of trauma and increasing healthcare expenditure worldwide.
The global plasma therapy market is expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% from 2016 to 2021.
The global market is segmented on the basis of type, source, application, end user, and region.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186196333
Geographically, the market is led by North America, followed by Europe, Asia-Pacific, and rest of the world (RoW). Growth in the global market is primarily driven by the increase in aging population and rise in the number of orthopedic disorders.
Top Key Players
Major players in the plasma therapy market include BioLife Plasma Services (U.S.), Cambryn Biologics LLC (U.S.), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), and Octapharma (Switzerland).
Target Audience for this Report:
Platelet-rich Plasma (PRP) Manufacturers and Suppliers
Academic Research Institutes
Hospitals & Clinics
Research & Development (R&D) Companies
Business Research & Consulting Service Providers
Medical Research Laboratories
Academic Medical Centers & Universities
North America led the global market, followed by Europe, Asia-Pacific, and rest of the world (RoW). Major players operating in Plasma Therapy Market include BioLife Plasma Services (U.S.), Cambryn Biologics LLC (U.S.), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), and Octapharma (Switzerland).
To Know More @ https://www.marketsandmarkets.com/PressReleases/plasma-therapy.asp